Humanigen Sets Date for Virtual Annual Shareholders Meeting

Humanigen Sets Date for Virtual Annual Shareholders Meeting




Humanigen Sets Date for Virtual Annual Shareholders Meeting

BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, announced today that its board of directors has scheduled the corporation’s 2021 Annual Meeting of Shareholders (the “Meeting”) for June 17, 2021 in a virtual-only format via the internet. The record date for shareholders to vote at the meeting is April 21, 2021.

Additional information confirming how shareholders may vote before or during the Meeting, as well as the time of the virtual Meeting and how to access it as a shareholder, will be included in the company’s proxy statement to be separately provided to shareholders. In order to streamline the virtual meeting process, the company strongly encourages shareholders to vote in advance of the Meeting.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization, and gene-knockout platforms. Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. Humanigen’s immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. Humanigen is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter and Facebook.

Contacts

Humanigen Media
Grace Catlett

RXMD

Gcatlett@rxmedyn.com
516-318-8563

Humanigen Investors
Alan Lada

Solebury Trout

ALada@SoleburyTrout.com
617-221-8006